Acute G-CSF therapy is not protective during lethal E. coli sepsis

Am J Physiol Regul Integr Comp Physiol. 2001 Oct;281(4):R1177-85. doi: 10.1152/ajpregu.2001.281.4.R1177.

Abstract

We investigated whether decreases in circulating polymorphonuclear neutrophils (PMN) during lethal Escherichia coli (E. coli) sepsis in canines are related to insufficient host granulocyte colony-stimulating factor (G-CSF). Two-year-old purpose-bred beagles had intraperitoneal E. coli-infected or -noninfected fibrin clots surgically placed. By 10 to 12 h following clot, both infected survivors and nonsurvivors had marked increases (P = 0.001) in serum G-CSF levels (mean peak G-CSF ng/ml +/- SE, 1,931 +/- 364 and 2,779 +/- 681, respectively) compared with noninfected controls (134 +/- 79), which decreased at 24 to 48 h. Despite increases in G-CSF, infected clot placement caused delayed (P = 0.06) increases in PMN (mean +/- SE change from baseline in cells x 10(3)/mm(3) at 24 and 48 h) in survivors (+3.9 +/- 3.9 and +13.8 +/- 3.6) compared with noninfected controls (+13.1 +/- 2.8 and +9.1 +/- 2.5). Furthermore, infected nonsurvivors had decreases in PMN (-1.4 +/- 1.0 and -1.1 +/- 2.3, P = 0.006 compared with the other groups). We next investigated whether administration of G-CSF immediately after clot placement and continued for 96 h to produce more rapid and prolonged high levels of G-CSF after infection would alter PMN levels. Although G-CSF caused large increases in PMN compared with control protein from 2 to 48 h following clot in noninfected controls, it caused much smaller increases in infected survivors and decreases in infected nonsurvivors (P = 0.03 for the ordered effect of G-CSF comparing the three groups). Thus insufficient host G-CSF is unlikely the cause of decreased circulating PMN in this canine model of sepsis. Other factors associated with sepsis either alone or in combination with G-CSF itself may reduce increases or cause decreases in circulating PMN.

MeSH terms

  • Animals
  • Blood Pressure / drug effects
  • Bronchoalveolar Lavage Fluid / cytology
  • Cell Count
  • Disease Models, Animal
  • Disease Progression
  • Dogs
  • Escherichia coli Infections / drug therapy*
  • Escherichia coli Infections / pathology
  • Granulocyte Colony-Stimulating Factor / adverse effects
  • Granulocyte Colony-Stimulating Factor / blood
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Heart Function Tests / drug effects
  • Myocardium / metabolism
  • Neutrophils / pathology
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Sepsis / drug therapy*
  • Sepsis / pathology
  • Survival Rate
  • Treatment Failure

Substances

  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor